



HAL
open science

Self-assembled Ln(III) cyclen-based micelles and AuNPs conjugates as candidates for luminescent and magnetic resonance imaging (MRI) agents

Jennifer Molloy, Aline Nonat, John O'brien, Dermot Brougham, Thorfinnur Gunnlaugsson

► To cite this version:

Jennifer Molloy, Aline Nonat, John O'brien, Dermot Brougham, Thorfinnur Gunnlaugsson. Self-assembled Ln(III) cyclen-based micelles and AuNPs conjugates as candidates for luminescent and magnetic resonance imaging (MRI) agents. *Supramolecular Chemistry*, 2020, 32 (6), pp.373-382. 10.1080/10610278.2020.1742912 . hal-02937964


HAL Id: hal-02937964

<https://hal.science/hal-02937964v1>

Submitted on 15 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.




L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Ln(III) cyclen-based micelles and AuNPs conjugates as candidates for luminescent and magnetic resonance imaging (MRI) agents

Journal:	<i>Supramolecular Chemistry</i>
Manuscript ID	Draft
Manuscript Type:	Full Paper
Date Submitted by the Author:	n/a
Complete List of Authors:	Gunnlaugsson, Thorfinnur; Trinity College Dublin, Chemistry Molloy, Jennifer; Université Grenoble Alpes, Département de Chimie Moléculaire Nonat, Aline; Université de Strasbourg, SynPA, IPHC, UMR 7178 O'Brien, John; Trinity College Dublin, Chemistry Brougham, Dermot ; University College Dublin School of Chemistry and Chemical Biology
Keywords:	lanthanides, MRI contrast agents, Gold nanoparticles, lanthanide luminescence, cyclen

SCHOLARONE™
Manuscripts



Cited as:

Molloy, J. K., Nonat, A. M., O'Brien, J. E., Brougham, D. F. & Gunnlaugsson, T. (2020). Self-assembled Ln(III) cyclen-based micelles and AuNPs conjugates as candidates for luminescent and magnetic resonance imaging (MRI) agents. *Supramol. Chem.* 32, 373-382. doi: <http://dx.doi.org/10.1080/10610278.2020.1742912>.

Ln(III) cyclen-based micelles and AuNPs conjugates as candidates for luminescent and magnetic resonance imaging (MRI) agents

Jennifer K. Molloy,^{*1,2} Aline M. Nonat,^{*2,3} John E. O'Brien,² Dermot F. Brougham⁴ and Thorfinnur Gunnlaugsson^{*2}

a. *Département de Chimie Moléculaire, UMR 5250, Université Grenoble Alpes, CNRS CS 40700, 38041, Grenoble cedex 9, France.*

b. *School of Chemistry and Trinity Biomedical Sciences Institute, Trinity College Dublin, The University of Dublin, Dublin 2, Ireland. gunnlaug@tcd.ie*

c. *SynPA, IPHC, UMR 7178, Université de Strasbourg, ECPM, 25 rue Becquerel, 67087 Strasbourg Cedex 02, France.*

d. *School of Chemistry, University College Dublin, Belfield, Dublin 4, Ireland.*

Corresponding Author:

Professor Thorfinnur Gunnlaugsson

School of Chemistry and Trinity Biomedical Sciences Institute

The University of Dublin, Trinity College Dublin

Dublin 2, Ireland

gunnlaug@tcd.ie

Telephone: +3531-896 3459

Acknowledgements

We thank IRCSET, Science Foundation Ireland (SFI PI Award 13/IA/1865 to TG) and the School of Chemistry, TCD for financial support.

Ln(III) cyclen-based micelles and AuNPs conjugates as candidates for luminescent and magnetic resonance imaging (MRI) agents

Abstract

The luminescent lanthanide tetra-substituted cyclen (1,4,7,10-tetraazacyclododecane) based Eu(III), Tb(III), Gd(III) and Lu(III) complexes (1.Ln and 2.Ln) and the corresponding functionalised gold nanoparticles (1.Ln-AuNP) were developed for use in the formation of luminescent self-assembling ternary structures and as Gd-based MRI contrast agents. Nanoassemblies with spin-lattice relaxivities (r_1) of 11.1 and 445 s⁻¹mM⁻¹ respectively (at 400 MHz) were obtained, rationalised by a micellar arrangement of the 1.Gd complex or by the conjugation to AuNPs.

Keywords: supramolecular chemistry, lanthanides, cyclen complexes, luminescence, MRI contrast agents, gold nanoparticles.

1. Introduction

The formation of smart imaging agents for use in both biochemical and medical applications is a topical area of research.^{1,2} In that area, the use of structures (such as fluorophores) that can self-assemble into higher order supramolecular assemblies,³ or be used for surface functionalization,⁴ is highly desirable.⁵ In particular, dual modal contrast agents with optical imaging and magnetic resonance imaging (MRI) properties can combine the excellent anatomical and spatial resolution of MRI with the acute sensitivity of optical based imaging probes.^{3,4,6} In the past we have developed several examples of targeting luminescent sensors, probes and MRI imaging agents.⁷ Given their remarkable biocompatibility and versatile surface functionalization,^{1,8} gold nanoparticles (**AuNPs**) have received significant interest for use in multiple imaging technologies.^{1e,9}

We have shown that lanthanide based AuNPs can be used in pH and anion sensing, as well as in luminescent imaging of microcracks in bones, using Eu(III) tetra-substituted cyclen (1,4,7,10-tetraazacyclododecane) systems.¹⁰ Cyclen-based^{1f} Gd(III) complexes are also excellent candidates for developing MRI contrast agents and they are currently used in approximately 40% of all MRI examinations, *e.g.* about 40 million administrations of [Gd(DOTA)]⁻ annually.^{5b} Recent research has demonstrated that higher longitudinal relaxivities (¹H T₁ relaxation enhancements per mM agent) are, however, required to enable targeted and molecular imaging or to improve contrast-enhanced brain tumour MRI imaging. Systems such as particles can act as platforms to achieve that,⁶ as this allows (*i*) an increase in the Gd(III) content (*via* the incorporation of several Gd(III) complexes on the same nano-object, aggregates, *etc.*),⁸ and; (*ii*) a reduction in the tumbling rate of the complexes. Examples of macromolecular hybrid systems that have recently been developed with this in mind,^{2a} include: dendrimers, micelles and peptides,^{9,11} carbon nanotubes¹² and nanoparticles.¹³ In this communication we demonstrate that unsaturated tetra-substituted cyclen-based lanthanide complexes possessing a hydrophobic tail (with or without a terminal thiol) can be used in the construction of nano-based dual imaging probes capable of both luminescent sensing^{14,15} and MRI contrast enhancement. We present two types of complexes based on a tri-acetamide derived cyclen ligand **1.Ln** and **2.Ln**, Figure 1; the former containing a terminal thiol group to facilitate functionalization of **AuNPs** and the second a dodecane chain, which we have recently shown can promote the formation of micelles¹⁶. We demonstrate that the Eu(III) complexes of **1** and **2** form luminescent ternary complexes with β -diketonates such as **nta** (4,4,4-trifluoro-1-(2-naphthyl)butane-1,3-dione) and **tta** (4,4,4-Trifluoro-1-(2-thienyl)-1,3-butanedione) and

1
2
3 that the Gd(III) complexes of these ligands give significant enhancement of the
4
5 longitudinal ^1H relaxivity (MRI contrast efficiency).
6
7
8
9

10 **2. Results and Discussion**

11 12 13 **2.1 Synthesis and characterisation studies**

14
15 The synthesis of ligand **1** was carried out by monoalkylation of cyclen,^{14,15}
16
17 alkylation of the remaining six amines with bromoacetamide, followed by
18
19 reductive cleavage of the disulfide bridge, which formed **1** in overall 20 % yield
20
21 over the 3 steps (*c.f.* characterisation in SUPPORTING INFORMATION). The
22
23 model compound **2**, which lacks the terminal thiol group, was formed using a
24
25 similar synthetic strategy. This compound was chosen to act as a control as the
26
27 thiol may partially displace one of the metal bound water molecules in H_2O and
28
29 buffered solution, as we previously observed in the development of NIR based
30
31 **Yb-AuNP** pH sensors.¹⁰ The corresponding lanthanide complexes **x.Ln** where $x=$
32
33 **1** and **2**, using Eu(III), Gd(III) and Tb(III), were then formed by complexation of **1**
34
35 and **2** with 1.1 eqs. of the corresponding $\text{Ln}(\text{CF}_3\text{SO}_3)_3$ in yields ranging from 70-
36
37 **1** and **2**, using Eu(III), Gd(III) and Tb(III), were then formed by complexation of **1**
38
39 and **2** with 1.1 eqs. of the corresponding $\text{Ln}(\text{CF}_3\text{SO}_3)_3$ in yields ranging from 70-
40
41 85 %, after precipitation and conventional workup (See ESI).
42
43

44
45 The synthesis of **AuNP-1.Ln** ($\text{Ln} = \text{Eu(III)}, \text{Tb(III)}, \text{and Gd(III)}$) was achieved with
46
47 modification^{10a,14} of the two-phase Brust-Schiffrin method.¹⁷ Phase transfer was
48
49 achieved with **1.Ln** in H_2O to form **1.Ln-AuNPs**, which were characterized by
50
51 measuring the UV-Vis absorption spectrum in H_2O . The characteristic plasmon
52
53 (SPR) band of the **AuNPs** at 520 nm was indicative of the formation of gold
54
55 nanoclusters of size in the 2- 10 nm range (*c.f.* SUPPORTING INFORMATION).
56
57
58
59
60

Moreover, this band was indicative of very good stability of the particles in water, as no measurable changes were detected over a period of six months.

Transmission electron microscopy (TEM) images of **1.Eu-AuNPs** also showed the formation of spherical monodisperse nanoparticles with an average diameter of 5 nm (standard deviation 0.3 nm, Figure 2 left) and no evidence of aggregation, which often can occur, as we have demonstrated in the formation of Ru(II)-polypyridyl based **AuNPs**,^{7a,b} Figure 2. The size distribution was further confirmed using dynamic light scattering (DLS), which shows the formation of particles of approximate size 5 nm for **1.Eu-AuNPs**, Figure 2 right. These particles were found to be stable in aqueous media over period of many months. Having synthesised and characterised **1.Ln**, **2Ln** and **1.Ln-AuNPs**, we next set out to investigate their photophysical properties,^{14,18-20} in aqueous media, in the absence and the presence of the antennae **nta** and **tta**.

2.2 Photophysical studies of Eu(III), Tb(III) complexes and Ln-AuNPs

The excited state lifetimes (τ) of the complexes, **1.Ln**, in both D₂O (τ = 0.93 ms for **1.Eu** and 1.6 ms for **1.Tb**) and H₂O (τ = 0.44 ms for **1.Eu** and 0.64 ms for **1.Tb**) were measured, which in both cases gave the hydration number, q (the number of metal bound water molecules) as 1.¹⁸ The results are summarised in Table 1. These complexes are designed to be hepta coordinated,^{19,20} and hence, one would expect q to be 2, to fulfil the high coordination number of both Eu(III) or Tb(III). However, for other thiol containing cyclen systems we have seen that the thiol functional group can coordinate to the ion reducing the overall hydration state,^{10a-b} so suggest that a similar effect is operating here. The lifetimes of

1
2
3
4 **1.Eu-AuNPs** and **1.Tb-AuNPs** were also determined; the same trend as the free
5
6 complex was observed; with $\tau = 1.67$ and 2.7 ms (in D_2O) and $\tau = 0.64$ and 1.6
7
8 ms (in H_2O) for **1.Eu-AuNPs** and **1.Tb-AuNPs**, respectively. While conjugation to
9
10 the **AuNPs** reduces all the lifetimes, the fact that the trends are retained
11
12 demonstrates that conjugation to the particles does not significantly alter the
13
14 coordination environment of the lanthanide ion, and q remains unchanged at
15
16 ~ 1 . In contrast, the model compound **2.Ln** (which lacks the terminal thiol)
17
18 demonstrated lifetimes of $\tau = 1.14$ ms for **2.Eu** in D_2O and $\tau = 0.52$ ms for **2.Eu** in
19
20 H_2O , consistent with the presence of two metal bound water molecules, as
21
22 expected for such coordinatively unsaturated structures.
23
24
25
26

27
28 Metal-bound solvent molecules are known to quench the luminescence of
29
30 lanthanides due to the presence of OH oscillators¹⁸ and thus the utilization of
31
32 these complexes in luminescent imaging requires the replacement of the metal
33
34 bound water molecules to form ternary complexes. To investigate this, the
35
36 “switching on” of the Eu(III) entered emission, and the concomitant formation of
37
38 **1.Eu** and **1.Eu-nta** was monitored by luminescence titration using the **nta**
39
40 antenna upon excitation at 330 nm, Figure 3 and 4, respectively. As as can be
41
42 seen in Figure 3, the Eu(III) centred emission of **1.Eu-nta** was similarly “switched
43
44 on”, but at much higher equivalents than seen for **1.Eu** (see discussion below).
45
46 The formation of the ternary complex between the antennae and the
47
48 complexes was evident from the enhancement in the line-like emission bands at
49
50 580, 595, 616, 650, and 700 nm, assigned to the characteristic population of the
51
52 5D_0 excited state, which deactivated to the 7F_J ($J = 0, 1, 2, 3,$ and 4) ground state.
53
54 Of these, the hypersensitive $\Delta J = 2$ transition, centred at 616 nm, is particularly
55
56
57
58
59
60

1
2
3 sensitive to the coordination environment of the Eu(III) centre, demonstrating
4 direct coordination to the metal ion upon replacement of the water molecules,
5
6 as was evident from lifetime measurements which resulted in determination of
7
8 q as 0. Plotting the changes in the $\Delta J = 2$ transition as a function of **nta**
9
10 equivalents showed an emission plateau after the addition of one equivalent
11
12 (inset Figure 3) demonstrating 1:1 binding between the bidentate antenna, **nta**,
13
14 and **1.Eu**. The titration of **1.Eu** with **tta** also demonstrated 1:1 binding; the
15
16 emission being switched on in an identical manner to that for **nta**. The reference
17
18 compound **2.Eu** demonstrated the same trend, and confirmed the 1:1
19
20 stoichiometry; showing that the complexes had similar coordination spheres to
21
22 that seen for **1.Eu**.
23
24
25
26
27
28
29

30 As expected, due to the presence of two metal bound water molecules, the
31
32 corresponding Tb(III) complexes were initially found to be non-luminescent in
33
34 HEPES buffered solution (pH 7.4, NaCl 0.1 M ionic strength). However, as in the
35
36 case of Eu(III), they gave rise to the formation of luminescent ternary adducts
37
38 with 1:1 stoichiometry upon titration with suitable antennae (that can populate
39
40 the 5D_4 excited state of Tb(III))^{14,24} such as benzoic acid and terephthalic acid,
41
42 chosen due to their triplet state levels (See SUPPORTING INFORMATION) for
43
44 both **1.Tb** and **2.Tb**, confirming the results above for Eu(III).
45
46
47
48
49

50 Having established that both complexes could be employed for the formation
51
52 of ternary complexes in competitive media, we carried out similar titration using
53
54 **1.Eu-AuNPs** in the same media. The results are shown in Figure 4,
55
56 demonstrating that upon stepwise formation of the ternary complexes on the
57
58 **AuNPs** the emission was 'switched on' in a similar manner to that of **1.Eu** alone.
59
60

1
2
3 We have previously demonstrated that such progressive 'switching on' is highly
4 depended on the number of complexes on the surface of the **AuNP**.^{14,15a} The
5 overall titration profile (from 0→250 equivalents of the antenna) is shown as
6 inset in Figure 4, showing a 10-fold increase in the Eu(III) centred emission; this
7 enhancement corresponding to the displacement of the hydration molecules of
8 the surface-bound complexes. The concentration of **AuNPs** can be determined
9 using the SPR of the particles; for which a plateau was observed upon addition
10 of 50 equivalents of **nta**. Consequently, using the 1:1 stoichiometry determined
11 above, it can be estimated that 50 **1.Eu** were present on the surface of the
12 particle **AuNP** in **1.Eu-AuNPs**; which is in good agreement with our previous
13 work using Ln-functionalised **AuNPs**.¹⁴ This was further confirmed by carrying
14 out such titrations using **1.Tb-AuNPs**; the Tb(III) emission also being switched on
15 within a similar equivalents range of the antenna. As the **1.Eu-AuNP** conjugates
16 were developed for potential applications such as luminescent sensing and
17 imaging, the effect of pH on the luminescent properties of **1.Ln** and **1.Ln-AuNP**
18 was evaluated for their stability and photophysical response over a broad pH
19 range from 2-12. Gratifyingly, the change in pH results only in a small
20 bathochromic shift in the antenna band at 339 nm with a concomitant
21 hyperchromic shift (See SUPPORTING INFORMATION) whereas the band at 265
22 nm band experienced a hypochromic shift. The pH-luminescent profile also
23 demonstrated (See SUPPORTING INFORMATION) that **1.Eu-AuNPs-nta** was
24 most luminescent construct at physiological pH; making it a particularly
25 attractive nano-system for bio-applications. Having confirmed the presence of
26 metal ion bound water molecules in **1.Eu** and **1.Eu-AuNPs** over a wide pH range,
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the isostructural gadolinium complexes **1.Gd** and **1.LGd-AuNPs** were prepared
4
5 and investigated as potential nanostructured MRI contrast agents.
6
7
8
9

10 **2.3 Relaxivity measurements of Gd(III) complexes and AuNP conjugate**

11 The efficiency of Gd(III) complexes in aqueous media for enhancing contrast in
12 T_1 -weighted MRI is quantified by the ^1H relaxivity $r_1 = [(1/T_1) - (1/T_1)_{\text{Gd}=0}] / [\text{Gd}]$.
13
14 The results of the relaxivity measurements for **1.Gd** are shown in Figure 5, and
15 demonstrate an r_1 value of $11.1 \text{ s}^{-1}\text{mM}^{-1}$ at 400 MHz, which is surprisingly high in
16 comparison to previously reported mono-aquo Gd(III) of similar molecular
17 weight.²¹ This suggests organization of this complex into more complex
18 architectures in solution; very likely due to the formation of assemblies such as
19 micelles which alter the dynamics about the metal ion. In order to assess the
20 rotational dynamics of the complex **1.Gd** at this concentration ($C_{\text{Gd}} = 2.67 \text{ mM}$), it
21 became thus apparent that it was important to estimate its hydrodynamic
22 radius (r_H) under these conditions. This value can be obtained by measuring the
23 translational diffusion coefficient by PFG-NMR with application of the Stokes-
24 Einstein Model.²² The diffusion coefficients of **1.Eu** and **1.Lu** ($D = 2.89$) were thus
25 determined in D_2O at 298 K, from which a r_H value of 60 \AA was determined for
26 both complexes. This value is much larger than expected for complexes of this
27 size; suggesting the formation of aggregates/micelles, which was further
28 confirmed by DLS measurements which, despite the inevitable strong size
29 dependent weighting, also showed the presence of aggregates with r_H between
30 50-100 Å . Luminescence lifetime measurements, performed on **1.Eu** at the same
31 concentration ($\tau_{\text{H}_2\text{O}} = 0.44 \text{ ms}$ and $\tau_{\text{D}_2\text{O}} = 0.93 \text{ ms}$), indicated that the
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 coordination sphere of the Eu(III) was unchanged upon micelle formation, and
4
5 the Ln(III) complexes remained as heptacoordinate (*e.g.* $q = 1$). An approximate
6
7 value of the critical micelle concentration was also determined by NMR PFG-
8
9 NMR and DLS to be 0.15×10^{-3} M. Hence, the results indicate that the
10
11 organization of **1.Gd** into micellar structures with slow tumbling rates, together
12
13 with fast water-exchange rate of the one metal-bound water molecule, are the
14
15 likely cause of the unusually high relaxivities measured at $C_{Gd} = 2.67$ mM.
16
17
18
19

20
21 NMR and DLS studies were also undertaken for both **2.Eu** and **2.Lu** within the
22
23 same concentration range of $0.1 \rightarrow 10$ mM. These results (See SUPPORTING
24
25 INFORMATION) indicated the absence of any aggregates for **2.Eu** and **2.Lu**;
26
27 suggesting that, as expected, the thiol terminal group is key to the formation of
28
29 aggregates for **1.Ln**. This finding was also confirmed by the relaxivity studies for
30
31 **2.Gd**; with a significantly lower relaxivity value of $r_1 = 5.80 \text{ s}^{-1}\text{mM}^{-1}$ at 400 MHz
32
33 as compared to **1.Gd**, which is more typical of that anticipated for bis-aquo
34
35 complexes of this size. For instance, r_1 values ranging from 5.6 to $10.5 \text{ s}^{-1}\text{mM}^{-1}$,
36
37 at 25 °C and 20 MHz, have previously been measured, under similar conditions,
38
39 for the HOPO-based Gd(III) complexes $[\text{Gd}(\text{DO3A})(\text{H}_2\text{O})_2]$.²³ We suggest that the
40
41 role of thiol group in supramolecular structure formation is to promote the
42
43 formation of a hydrophobic pocket with the charged Ln(III) complexes acting as
44
45 a hydrophilic head. Hence, these results suggest thiol-functionalised derivatives
46
47 as particularly attractive targets for the design of new high relaxivity micellar
48
49 structures.
50
51
52
53
54
55

56
57 The conjugation of the complexes onto **AuNPs** to form **1.Gd-AuNPs** might be
58
59 expected to further increase the relaxivity by reducing the tumbling rates, in any
60

1
2
3
4 case high lanthanide loading per particle (c.50 Gd(III) ions per **AuNP**) is also
5
6 advantageous. The longitudinal ^1H r_1 value of **1.Gd-AuNP** was found to be 4.42 s^{-1}
7
8 mM^{-1} , at 2.67 mM (Gd) and 400 MHz. The relaxivity per **AuNP** was found to be
9
10 significantly larger than was observed for the **1.Gd** micellar systems, probably
11
12 due to the very high Gd content on the AuNPs. Analysis of the relaxivity of **1.Gd-**
13
14 **AuNP** as a function of temperature, demonstrated a decrease in r_1 with
15
16 increasing temperature. This suggests that the water exchange rate at room
17
18 temperature is not a limiting factor for the relaxivity. Nevertheless the
19
20 measured NMRD profile is not indicative of slow rotation with fast water
21
22 exchange rate. Moreover, a lower relaxivity of $4.42 \text{ mM}^{-1}\text{s}^{-1}$ per Gd(III) ion
23
24 compared to the value for free **2.Gd** of $5.8 \text{ mM}^{-1}\text{s}^{-1}$ at 400 MHz, suggests that at
25
26 the attainable grafting density any restriction to internal dynamics conferred by
27
28 particle grafting had little effect on the relaxivity. This is potentially due to
29
30 internal rotation due to the flexible alkyl chain.
31
32
33
34
35
36
37
38

39 **3. Conclusion**

40
41 Herein, we have developed and investigated a series Ln-complex of **1**; **1.Eu**, **1.Gd**
42
43 and **2.Eu** and **2.Gd** and the conjugated **1.Ln-AuNPs** nano-structures. Our results
44
45 demonstrate that each **1.Ln** complex contained a single metal bound water
46
47 molecule; both in the free complexes and upon surface conjugation to **AuNPs**. In
48
49 contrast, **2.Ln**, which lacks the terminal thiol group in **1.Ln**, were formed with q
50
51 $=2$. The photophysical properties of the **1.Eu** and **1.Tb** analogues were also
52
53 studied; and the presence of one inner sphere water molecule, and the
54
55 formation of luminescent ternary complexes with the **nta** and **tta** antennae, was
56
57
58
59
60

confirmed. We also shown that the **1.Gd** complex has a relatively high relaxivity of $11.5 \text{ mM}^{-1}\text{s}^{-1}$ compared to other similar mono-aquo cyclen complexes, which we attribute to the formation of aggregates, or micellar formation in solution; with a CMC of $0.15 \times 10^{-3} \text{ M}$. **1.Ln-AuNPs** nanostructures were also characterized, and shown to possess a high relaxivity due to high loading of (*ca.* 50) **1.Gd** complexes per **AuNP**. However, the relaxivity per Gd ion remains limited by a fast τ_R , probably due to flexible chains allowing free rotation. To conclude, the work herein supports our endeavour to develop novel and potential bimodal supramolecular nano-agents possessing both luminescent and magnetic Ln(III) properties. Future work will be directed towards the formation of functional bimodal systems for the development of more targeted/responsive contrast agents.

4. Experimental

2,2',2''-(10-(12-Mercaptododecyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetamide

Mercaptododecanyl tetraazacyclododecane (0.123 g, 0.332 mmoles, 1eq.) was dissolved in CH_3CN with K_2CO_3 (0.151 g, 1.1 mmoles, 3.3 eq.) and KI (0.176 g, 1.1 mmoles, 3.3 eq.). Bromoacetamide (0.15 g, 1.1 mmoles, 3.3 eq.) was added to the solution and the solution stirred for 5 days at $85 \text{ }^\circ\text{C}$. Reductive cleavage with NaBH_4 (2eq.), followed by washing with water, dried over MgSO_4 , filtered and solvent removed followed by two precipitations in ether and methanol yielded the product as a yellow clear oil 0.090 g, 51% yield. HRMS (m/z -ES+) Found for $\text{C}_{26}\text{H}_{54}\text{N}_7\text{O}_3\text{S}$: 544.4026, Required 544.4009; δ_{H} (MeOD, 400 MHz): 3.26 (CH_2), 3.18 (CH_2), 3.02 (CH_2), 1.70 (CH_2),

1
2
3 1.51 (CH₂), 1.30 (CH₂ chain). δ_c (MeOD, 100 MHz): 175.7(q), 175.1(q), 169.3(q), 56.8
4
5 (Cyclen CH₂), 56.5 (Cyclen CH₂), 54.6 (Cyclen CH₂), 54.4 (CH₂), 51.3(CH₂), 51.2 (CH₂),
6
7 50.7 (CH₂), 50.1 (CH₂), 38.8 (CH₂), 29.8 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.64 (CH₂), 29.58
8
9 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 27.9 (CH₂), 27.8 (CH₂),
10
11 25.2 (CH₂), 7.1 (CH₂). ν_{max} (neat sample)/ cm⁻¹: 3361, 3314, 3170, 2924, 2853, 2820,
12
13 1697, 1680, 1446, 1371, 1332, 1284, 1256, 1102, 1008, 907, 811, 722, 675.
14
15
16
17
18
19
20

21 **General Procedure for the synthesis of 1.Ln**

22
23 Ligand **1** was dissolved in MeOH with 1.1 eq. of Ln (CF₃SO₃)₃ and refluxed overnight
24
25 under argon. Solvent was removed under reduced pressure and the resulting residue
26
27 was precipitated out of swirling diethyl ether to yield 1.Ln as yellow oils.
28
29
30
31
32

33 **1.Gd** was isolated as a yellow oil, 0.0398 g, 47 % yield. HRMS (MALDI): Found 1186.14
34
35 for [**43.Gd** + (CF₃SO₃)₃ + K⁺] Calculated: 1186.6786. ν_{max} (neat sample)/ cm⁻¹: 3350,
36
37 3334, 2924, 2853, 1659, 1621, 1457, 1367, 1272, 1246, 1166, 1085, 1029, 915, 878,
38
39 834, 766, 720, 650.
40
41
42
43
44

45 **1.Eu**

46
47 **1** (0.016 g, 0.0294 mmoles, 1eq.) was refluxed in MeOH with Eu(CF₃SO₃)₃ (0.019g,
48
49 0.0324 mmoles, 1.1eq.) to yield 0.0157 g, 77 % yield. δ_H (MeOD, 400 MHz): -17.4, -
50
51 15.35, -13.89, -11.6, -10.3, -8.7, -8.09, -7.8, -6.9, -5.5, -4.90, -3.05, -1.35, 0.29, 0.90,
52
53 1.34, 1.69, 2.02, 2.16, 2.70, 3.01, 3.14, 3.32, 3.35, 3.49, 3.63, 3.64, 3.69, 3.75, 4.05,
54
55 4.94, 5.5, 6.4, 8.1, 9.83, 13.53, 17.32, 18.45. ν_{max} (neat sample)/ cm⁻¹: 3353, 3187, 2928,
56
57 2856, 1660, 1597, 1466, 1248, 170, 1083, 1028, 918, 832.
58
59
60

1.Lu

1 (0.028 g, 0.05 mmoles, 1 eq.) was dissolved in CH₃CN (10 mL) and the solution stirred with slow addition of Lu(CF₃SO₃)₃ (0.035 g, 0.056 mmoles, 1.1 eq.) to the solution followed by heating at reflux overnight. The solvent was reduced to 1 mL and the product precipitated out of ether to yield the product as a yellow oil 0.033 g, 92 % yield. δ_{H} (MeOD, 400 MHz): 3.86, 3.68, 3.48, 3.32, 3.19, 3.04, 2.99, 2.90, 2.83, 2.68, 2.20, 1.98, 1.69, 1.41, 1.30, 1.14; ν_{max} (neat sample)/ cm⁻¹: 3385, 3322, 3255, 2929, 2859, 1672, 1603, 1469, 1226, 1171, 1081, 1028, 917, 884, 837, 764.

1.Tb

43 (0.029g, 0.0537 mmoles, 1eq.) was dissolved in CH₃CN (20 mL) and stirred under reflux overnight with Tb(CF₃SO₃)₃ (0.0358 g, 0.059 mmoles, 1.1eq.) followed by precipitation from swirling diethyl ether to yield the product as a yellow oil 0.0353g, 93.5 % yield. δ_{H} (MeOD, 400 MHz): -155.1, -141.7, -116.1, -85.34, -55.9, -24.15, -15.0, -14.4, -13.7, -10.28, -9.6, -5.40, -2.77, -2.73, -1.46, -0.47, 0.04, 0.19, 0.49, 0.99, 1.19, 1.38, 1.49, 2.09, 2.31, 2.49, 3.33, 3.78, 4.85, 7.01, 15.52 302.6, 304.6, 306.0. ν_{max} (neat sample)/ cm⁻¹: 3348, 3174, 2927, 2855, 1657, 1596, 1463, 1249, 1173, 1081, 1029, 919, 833.

2,2',2''-(10-Dodecyl-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetamide

Dodecanyl tetraazacyclododecane (0.336 g, 0.98 mmoles, 1eq.) was dissolved in CHCl₃ with K₂CO₃ (0.45 g, 3.3 mmoles, 3.3 eq.) and KI (0.541 g, 3.3 mmoles, 3.3 eq.) and stirred with addition of bromoacetamide (3.3 eq.) at 0 °C. The mixture was stirred for 7

1
2
3 days at 65 °C before filtration through a plug of celite and removal of solvent.
4
5
6 Extraction into CHCl_3 followed by washing with base, dried over MgSO_4 , filtered and
7
8 solvent removed under reduced pressure, yielded a white solid 0.0751 g, 15 % yield.
9
10 HRMS (m/z-MALDI) Found for $\text{C}_{27}\text{H}_{55}\text{N}_3\text{O}_3$: 534.4103, Required: 534.4108; δ_{H} (MeOD,
11
12 400 MHz): 8.39 (1H, s, NH_2), 8.02 (2H, s, NH_2), 7.11 (1H, s, NH_2), 6.17 (1H, s, NH_2), 5.96
13
14 (2H, s, NH_2), 5.48 (2H, s, NH_2), 3.06 (6H, m, CH_2) 2.34 - 2.69 (16H, m, Cyclen), 1.28 (22H,
15
16 m, CH_2), 0.89 (3H, m, CH_3). δ_{C} (MeOD, 100 MHz): 77.5 (CH_2), 77.2 (CH_2), 77.2 (CH_2),
17
18 77.1 (CH_2), 50.3 (CH_2), 50.0 (CH_2), 49.8 (CH_2), 49.6 (CH_2), 49.4 (CH_2), 49.3 (CH_2), 49.0
19
20 (CH_2), 31.9 (CH_2), 29.6 (CH_2), 29.5 (CH_2), 22.6 (CH_2), 14.1 (CH_2). ν_{max} (neat sample)/ cm^{-1} :
21
22 3356, 3257, 3167, 2919 (sharp), 2849, 1673, 1449, 1404, 1360, 1348, 1294, 1261,
23
24 1202, 1152, 1116, 1087, 1068, 1046, 1032, 1002, 979, 959, 923, 880, 803, 718, 669.
25
26
27
28
29
30
31
32

33 General procedure for synthesis of 2.Ln

34
35 **2** was dissolved in MeOH and $\text{Ln}(\text{CF}_3\text{SO}_3)_3$ added to the mixture slowly. The solution
36
37 was then refluxed overnight followed by reduction of the solvent to 1 mL under
38
39 reduced pressure and precipitation out of swirling diethyl ether, which yielded the
40
41 product as a yellow oil.
42
43
44
45
46
47

48 2.Eu

49
50 **2** (0.0144 g, 0.028 mmoles, 1 eq.) and $\text{Eu}(\text{CF}_3\text{SO}_3)_3$ (0.0185 g, 0.031 mmoles, 1.1 eq.)
51
52 0.0097 g, 52 % yield. HRMS (m/z-MALDI) Found for $\text{C}_{27}\text{H}_{52}\text{N}_7\text{O}_6\text{F}_3\text{SEu}$, 812.2834,
53
54 Required: 812.2864; δ_{H} (MeOD, 400 MHz): 23.90, 21.56, 19.87, 19.09, 8.15, 7.92, 4.92,
55
56 3.69, 3.66, 3.49, 3.32, 3.05, 2.78, 2.66, 2.54, 2.05, 1.30, 0.92, 0.10, -.47, -1.19, -1.42, -
57
58 1.70, -2.30, -2.60, -5.04, -5.44, -6.36, -7.95, -8.44, -9.17, -9.67, -11.24, -11.49, -12.01, -
59
60

1
2
3 13.79, -16.97, -18.01, -18.66; ν_{\max} (neat sample)/ cm^{-1} : 3357, 2926, 2856, 1666, 1600,
4
5
6 1467, 1235, 1217, 1165, 1082, 1025, 914, 880, 831, 762.
7
8
9

10 **2.Gd**

11
12
13 **2** (0.0642 g, 0.125 mmoles, 1eq.) with $\text{Gd}(\text{CF}_3\text{SO}_3)$ (0.0462 g, 0.138 mmoles, 1.1 eq.)
14
15 yielded a white oily solid, 0.398 g, 47 % yield. HRMS (m/z -ES+) Found for
16
17 $\text{C}_{27}\text{H}_{52}\text{N}_7\text{O}_6\text{F}_3\text{SGd}$ 669.3474, Required: 669.3451. ν_{\max} (neat sample)/ cm^{-1} : 3367, 2930,
18
19 2856, 1603, 1467, 1237, 1217, 1164, 1079, 1025, 917, 880, 829, 764.
20
21
22
23
24
25

26 **AuNPs**

27
28 General Procedure: Tetrachloroaurate trihydrate was dissolved in Millipore water and
29
30 stirred vigorously on addition of toluene containing tetraoctylammonium bromide
31
32 (TOAB). The mixture was stirred vigorously at room temperature for 10 mins followed
33
34 by addition of NaBH_4 slowly. The mixture was then stirred at room temperature for 2
35
36 hours. On cessation of stirring the product separated into the toluene layer as a dark
37
38 purple solution. The product was extracted into toluene, washed with 0.1 M HCl, and
39
40 0.1 M NaOH followed by washing with H_2O . UV-vis absorption spectrum showed the
41
42 characteristic SPR band of the **AuNPs** at 530 nm.
43
44
45
46
47
48
49

50 **Eux.AuNP –General Synthesis**

51
52 A 1×10^{-3} solution of complex in $\text{MeOH}/\text{H}_2\text{O}$ was stirred vigorously on addition of
53
54 toluene solution of nanoparticulate gold. The resulting water layer upon transfer of
55
56 the gold to the complex solution turned deep purple showing stabilisation by the
57
58 complex of the nanoparticle in the aqueous layer. The layers were then separated and
59
60

1
2
3 the aqueous layer filtered through a 0.2 μm pore syringe filter in order to remove
4 possible aggregates. The resulting pink / purple solution (colour dependent on
5 concentration of gold) contained the stabilized nanoparticles and the SPR in the UV-vis
6 absorption spectrum could be seen to shift to approximately 520 nm.
7
8
9
10
11
12
13
14

15 **Relaxometric measurements**

16
17 The frequency dependence of the ^1H relaxation for the aqueous suspensions was
18 recorded over the frequency range of 0.01 – 40 MHz using a Singmaster FFC-2000 Fast
19 Field Cycling NMR Relaxometer (Stelar SRL, Mede, Italy). The system operated at a
20 measurement frequency of 16.3 MHz for ^1H , at which frequency the 90° pulse was 7
21 μs . T_1 measurements were performed as a function of external field, B_0 , with standard
22 pulse sequences incorporating B_0 field excursions. For higher frequency measurements
23 (40 – 80 MHz) a re-conditioned Bruker WP80 electromagnet was used. The temperature
24 of the samples was maintained at 25 ± 1 $^\circ\text{C}$ using a thermostatted airflow system. All of
25 the ^1H magnetisation recovery curves were singly exponential within experimental error
26 and the random errors in fitting T_1 were always less than 1%.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 **5. Supplementary Material**

45 NMR, UV-Vis absorption and Emission studies, TEM and DLS results and NMRD results.
46
47
48

49 **6. Acknowledgements**

50 We thank IRCSET, Science Foundation Ireland (SFI PI Award 13/IA/1865 to TG)
51 and the School of Chemistry, TCD for financial support.
52
53
54
55
56
57
58
59
60

7. References

1. (a) Wahsner, J.; Gale, E. M.; Rodríguez-Rodríguez, A.; Caravan, P.; *Chem. Rev.*, **2019**, *119*, 957–1057; (b) Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B.; *Chem. Rev.* **1999**, *99*, 2293–2352; (c) Poynton, F. E.; Bright, S. A.; Blasco, S.; Williams, D. C.; Kelly J. M.; Gunnlaugsson, T.; *Chem. Soc. Rev.*, **2017**, *46*, 7706–7756; (d) Wu, D.; Sedgwick, A. C.; Gunnlaugsson, T.; Akkaya, E. U.; Yoon J.; James, T. D.; *Chem. Soc. Rev.*, **2017**, *46*, 7105–7123; (e) Surender, S., E. M.; Kotova, O.; Truman, L. K.; Molloy J. K.; Gunnlaugsson, T.; *Inorg Chem.*, **2014**, *53*, 1867–1879; (f) Heffern, M. C.; Matosziuk L. M.; Meade, T. J.; *Chem. Rev.*, **2014**, *114*, 4496. (g) Gunnlaugsson T.; Parker, D.; *Chem. Commun.*, **1998**, 511–512; (h) Nonat, A. M.; Harte, A. J.; Senechal-David, K.; Leonard J. P.; Gunnlaugsson, T.; *Dalton Trans.*, **2009**, 4703–4711.
2. (a) Caravan, P. *Chem. Soc. Rev.* **2006**, *35*, 512–523. (b) Alric, C.; Taleb, J.; Le Duc, G.; Mandon, C.; Billotey, C.; Le Meur-Herland, A.; Brochard, T.; Vocanson, F.; Janier, M.; Perriat, P.; Roux S.; Tillement, O.; *J. Am. Chem. Soc.* **2008**, *130*, 5908–5915.; (c) Greish, K.; *J. Drug Target.* **2007**, *15*, 457–464. (d) Kunjachan, S.; Ehling, J.; Storm, G.; Kiessling, F.; Lammers, T.; *Chem. Rev.*, **2015**, *115*, 10907; (e) Amoroso, A. J.; Pope, S. J. A.; *Chem. Soc. Rev.*, **2015**, *44*, 4723. (f) Meledandri, C. J.; Brougham, D. F.; *Anal. Methods*, **2012**, *4*, 331; (g) Gun'ko, Y. K.; Brougham, D. F.; *Nanotechnologies for the Life Sciences*, Wiley-VCH, **2009**, *4*, 119–185.
3. (a) Savyasachi, A. J.; Kotova, O.; Shanmugaraju, S.; Bradberry, S. J.; Ó Máille, G. M.; Gunnlaugsson, T.; *Chem*, **2017**, *3*, 764–811. (b) Tallec, G.; Imbert, D.; Fries P. H.; Mazzanti, M.; *Dalton Trans.* **2010**, *39*, 9490–9492.
4. (a) Lacerda S.; Tóth, É.; *Chem. Med. Chem.* **2017**, *12*, 883–894; (b) Li, X.-Z.; Zhou, L.-P.; Yan, L.-L.; Yuan, D.-Q.; Lin C.-S.; Sun, Q.-F.; *J. of the Am. Chem. Soc.* **2017**, *139*,

- 8237-8244; (c) Goetz, J.; Nonat, A.; Diallo, A.; Sy, M.; Sera, I.; Lecointre, A.; Lefevre, C.; Chan, C.F.; Wong, K.-L.; Charbonnière, L. J.; *Chem. Plus. Chem.* **2016**, *81*, 526-534.
5. (a) Lohrke, J.; Frenzel, T.; Endrikat, J.; Alves, F. C.; Grist, T. M.; Law, T. M.; Lee, J. M.; Leiner, T.; Li, K. C.; Nikolaou, K.; Prince, M. R.; Schild, H. H.; Weinreb, J. C.; Yoshikawa K.; Pietsch, H.; *Adv. Ther.* **2016**, *33*, 1-28; (b) Hao, D.; Ai, T.; Goerner, F.; Hu, X.; Runge V. M.; Tweedle, M.; *J. Magn. Res. Imag.* **2012**, *36*, 1060-1071.
6. (a) Meola, A.; Rao, J.; Chaudhary, N.; Sharma M.; Chang, S. D.; *Gold Front. Neurol.* **2018**, *9*, 328. (b) Nicolay, K.; Strijkers G.; Grüll, H.; *The Chemistry of Contrast Agents in Medicinal Magnetic Resonance Imaging*, John Wiley & Sons, Ltd, **2013**, *11*.
7. (a) Martínez-Calvo, M.; Orange, K. N.; Elmes, R. B. P.; la Cour Poulsen, B.; Williams D. C.; Gunnlaugsson, T.; *Nanoscale*, **2016**, *8*, 563-574; (b) Elmes, R. B. P.; Orange, K. N.; Cloonan, S. M.; Williams D. C.; Gunnlaugsson, T.; *J. Am. Chem. Soc.*, **2011**, *133*, 15862-15865. (c) McMahon, B. K.; Mauer, P.; McCoy, C. P.; Lee T. C.; Gunnlaugsson, T.; *J. Am. Chem. Soc.*, **2009**, *131*, 17542. (d) Surender, E. M.; Bradberry, S. J.; Bright, S. A.; McCoy, C. P.; Williams D. C.; Gunnlaugsson, T.; *J. Am. Chem. Soc.*, **2017**, *139*, 381-388.
8. (a) Langereis, S.; Dirksen, A.; Hackeng, T. M.; van Genderen M. H. P.; Meijer, E. W.; *New J. Chem.* **2007**, *31*, 1152-1160. (b) Aime, S.; Castelli, D. D.; Crich, S. G.; Gianolio, E.; Terreno, E.; *Acc. Chem. Res.* **2009**, *42*, 822-831. (c) Lacerda, S.; Bonnet, C. S.; Pallier, A.; Villette, S.; Foucher, F.; Westall, F.; Buron, F.; Suzenet, F.; Pichon, C.; Petoud S.; Tóth, E.; *Small*, **2013**, *9*, 2662; (d) Debroye, E.; Laurent, S.; Elst, L. V.; Muller R. N.; Parac-Vogt, T. N.; *Chem. Eur. J.*, **2013**, *19*, 16019. (e) Poznik, M.; Maitrab U.; König, B.; *Org. Biomol. Chem.*, **2015**, *13*, 9789; (f) Iqbal, U.; Albaghdadi, H.; Nieh, M.; Tuor, U. I.; Mester, Z.; Stanimirovic, D.; Katsaras J.; Abulrob, A.; *Nanotechnology*, **2011**, *22*, 195102; (g) Terreno, E.; Boffa, C.; Menchise, V.; Fedeli, F.; Carrera, C.; Castelli, D. D.;

1
2
3
4 Digiliod G.; Aime, S.; *Chem. Commun.*, **2011**, 47, 4667; (e) Kozłowska, D.; Biswas, S.;
5
6 Fox, E. K.; Wu, B.; Bolster, F.; Edupuganti, O. P.; Torchilin, V.; Eustace, S.; Botta, M.;
7
8 O'Kennedy, R.; Brougham, D. F.; *RSC Adv.*, **2014**, 4, 18007.

9
10 9. (a) Lewis D. J.; Pikramenou, Z.; *Coord. Chem. Rev.*, **2014**, 273, 213; (b) Cheng, Z.;
11
12 Thorek, D. L. J.; Tsourkas, A.; *Angew. Chem. Int. ed.*, **2010**, 49, 346-350. c) Bonnet, C. S.;
13
14 Pellegatti, L.; Buron, F.; Shade, C. M.; Villette, S.; Kubicek, V.; Guillaumet, G.; Suzenet,
15
16 F.; Petoud S.; Tóth, É.; *Chem. Commun.*, **2010**, 46, 124;

17
18 10. (a) Surender, E. M.; Comby, S.; Cavanagh, B.; Brennan, O.; Lee T. C.; Gunnlaugsson,
19
20 T.; *Chem*, **2016**, 1, 438-455. (b) Truman, L. K.; Comby S.; Gunnlaugsson, T.; *Angew.*
21
22 *Chem. Int. Ed.*, **2012**, 51, 9624-9627; (b) Comby S.; Gunnlaugsson, T.; *ACS Nano.*, **2011**,
23
24 5, 7184-7197.

25
26 11. (a) Park, J.- A. ; Lee, J.-J.; Jung, J.-C.; Yu, D.-Y.; Oh, C.; Ha, S.; Kim, T.-J.; Chang, Y.
27
28 *Chem. Bio. Chem.* **2008**, 9, 2811-2813. (b) Nicolle, G. M.; Tóth, É.; Eisenwiener, K.-P.;
29
30 Mäcke, H. R.; Merbach, A. E. ; *J. Biol. Inorg. Chem.* **2002**, 7, 757-769; (c) Torres, S.;
31
32 Martins, J. A.; André, J. P.; Geraldés, C. F. G. C.; Merbach, A. E.; Tóth, É.; *Chem. Eur.*
33
34 *J.* **2006**, 12, 940-948.

35
36 12. Chen, K.; Chen, X.; *Curr. Top. Med. Chem.* **2010**, 10, 1227-1236.

37
38 13. (a) Park, J.-A.; Reddy, P. A. N.; Kim, H.- K.; Kim, I.-S.; Kim, G.-C.; Chang, Y.; Kim, T.-J.;
39
40 *Bioorg. Med. Chem. Lett.* **2008**, 18, 6135-6137; (b) Pansieri, J.; Plissonneau, M.;
41
42 Stransky-Heilkron, N.; Dumoulin, M.; Heinrich-Balard, L.; Rivory, P.; Morfin, J.-F.; Tóth,
43
44 É.; Saraiva, M. J.; Allémann, E.; Tillement, O.; Forge, V.; Lux, F.; Marquette, C.;
45
46 *Nanomedicine* **2017**, 12, 1675-1687. (c) Moriggi, L.; Cannizzo, C.; Dumas, E.; Mayer, C.
47
48 R.; Ulianov, A.; Helm, L.; *J. Am. Chem. Soc.* **2009**, 131, 10828-10829.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
14. Truman, L. K.; Bradberry, S. J.; Comby, S.; Kotova, O.; Gunnlaugsson, T.; *ChemPhysChem*, **2017**, *18*, 1746-1751.
15. (a) Massue, J.; Quinn, S. J.; Gunnlaugsson, T.; *J. Am. Chem. Soc.* **2008**, *130*, 6900-6901; (b) Bonnet, C. S.; Massue, J.; Quinn, S. J.; Gunnlaugsson, T.; *Org. Biomol. Chem.* **2009**, *7*, 3074-3078.
16. Surender, E. M.; Comby, S.; Martyn, S.; Cavanagh, B.; Lee, T. C.; Brougham, D. F.; Gunnlaugsson, T.; *Chem. Commun.* **2016**, *52*, 10858-10861.
17. (a) Brust, M.; Walker, M.; Bethell, D.; Schiffrin, D. J.; Whyman, R.; *J. Chem. Soc., Chem. Commun.* **1994**, 801-802. (b) Li, Y.; Zaluzhna, O.; Xu, B.; Gao, Y.; Modest, J. M.; Tong, Y. J.; *J. Am. Chem. Soc.* **2011**, *133*, 2092-2095.
18. (a) Supkowski, R. M.; Horrocks, W. D.; *Inorg. Chim. Acta*, **2002**, *340*, 44-48. (b) Beeby, A.; Clarkson, I. M.; Dickins, R. S.; Faulkner, S.; Parker, D.; Royle, L.; de Sousa, A. S.; Williams, J. A. G.; Wood, M.; *J. Chem. Soc., Perkin Trans. 2*, **1999**, 493-504.
19. Butler, S. J.; Parker, D.; *Chem. Soc. Rev.* **2013**, *42*, 1652-1666.
20. (a) Pope, S. J. A.; Burton-Pye, B. P.; Berridge, R.; Khan, T.; Skabara, P. J.; Faulkner, S. *Dalton Trans.* **2006**, 2907-2912. (b) Gunnlaugsson, T.; Harte, A. J.; Leonard, J. H. P.; Nieuwenhuyzen, M.; *Supramol. Chem.* **2003**, *15*, 505-519.
21. Powell, D. H.; Ni Dhubhghaill, O. M.; Pubanz, D.; Helm, L.; Lebedev, Y. S.; Schlaepfer, W.; Merbach, A. E.; *J. Am. Chem. Soc.* **1996**, *118*, 9333-9346.
22. Lycknert, K.; Rundlöf, T.; Widmalm, G.; *J. Phys. Chem. B.* **2002**, *106*, 5275-5280.
23. Datta, A.; Raymond, K. N.; *Acc. Chem. Res.* **2009**, *42*, 938-947.

Figure Captions

Figure 1 **Figure 1.** The Ln(III) cyclen complexes and antennae structures used in this study.

Figure 2. Left: TEM image of **1.Eu-AuNPs**, with size distribution inset (each bar representing 1-8 nm). Right: Dynamic Light Scattering (DLS) of **1.Eu-AuNPs** in H₂O from two different samples.

Figure 3: Figure 2: Changes in the Eu(III) emission of **1.Eu** ($c = 1 \times 10^{-5}$ M) in HEPES buffered solution (0.1 M, ionic strength 0.1M HCl) upon addition of **nta** (0-6 equivalents) *Inset:* The changes in the $\Delta J = 2$ transition versus the number of equivalents of **nta** added.

Figure 4: The changes in the Eu(III) emission of **1.Eu-AuNPs** (50 complexes per particle) (1×10^{-7} M of **AuNPs**) in HEPES buffer at pH 7.4 (0.1M, ionic strength 0.1M NaCl) upon the addition of **nta** from 0-250 equivalents. *Inset:* The changes in the $\Delta J = 2$ transition versus the number of equivalents of **nta** added.

Figure 5: Longitudinal relaxivity (r_1) of the protons of H₂O with **1.Gd** (Red squares) (2.67 mM) and **1.Gd-AuNP** (black squares), (2.7 mM) squares represent the r_1 per **AuNP**.

Figures

Figure 1:




Figure 2




Figure 3




Figure 4




Figure 5





Table 1. Lifetime analysis of the L(III) complexes and conjugates. These were fully reproducible.

Complex	$\tau_{\text{H}_2\text{O}}$ (ms)	$\tau_{\text{D}_2\text{O}}$ (ms)	q value (± 0.5)
1.Eu	0.44	0.93	1.5
4. Eu	0.52	1.14	1.7
1.Tb	2.65	1.5	1.0
1.Eu-AuNPs	0.64	1.6	1.5
1.Tb -AuNPs	2.70	1.67	0.7


1
2
3
4 **Ln(III) cyclen-based micelles and AuNPs conjugates as candidates for**
5 **luminescent and magnetic resonance imaging (MRI) agents**
6
7

8
9 Jennifer K. Molloy, Aline M. Nonat, John E. O'Brien, Dermot F. Brougham and
10
11 Thorfinnur Gunnlaugsson
12

13
14
15 **Figures**



33 **Figure S1:** Partial ^1H NMR spectrum (MeOD, 400 MHz) of ligand **1**



48 **Figure S2:** ^1H NMR spectrum (MeOD, 400 MHz) of **1.Eu**, showing the classical shifts in the
49 axial and equatorial protons of the cyclen ring.
50
51
52
53
54
55
56
57
58
59
60




Figure S3: ^1H NMR spectrum (MeOD, 400 MHz) of ligand **2**.




Figure S4: A) MALDI of **2.Eu** calculated and observed, B) MALDI of **2.Gd**, calculated and observed. The calculated and the observed isotopic distribution pattern of **2.Eu** and **2.Gd** obtained from the MALDI can be seen in Figure 1, which in the case of **2.Eu** was fitted to $\text{C}_{27}\text{H}_{52}\text{N}_7\text{O}_6\text{F}_3\text{SEu}$ with the calculated mass of 812.2864. Figure 1a, but similar results were observed for **2.Gd**, with an observed mass of 669.3474 for $\text{C}_{27}\text{H}_{52}\text{N}_7\text{O}_6\text{F}_3\text{SGd}$.




Figure S5: UV-Vis absorption spectrum of **1.Eu-AuNPs** in H₂O, showing the characteristic SPR band with λ_{max} at 520 nm. These particles were stable over time and no measurable change was observed after 6 months.




Figure S6: TEM images of **1.Ln-AuNP [Ln = a) Tb; b) Eu; c) Gd]**. Characterisation of the nanoparticles by TEM, showed monodisperse stabilised particles.




Figure S7: The size distribution of **1.Ln-AuNP [Ln =a) Tb; b) Eu; c) Gd]** determined from the TEM shown in Figure S6 above, was on average 5-6 nm, which are the size expected from the Brust method (Picture taken from the original analysis report).




Figure S8: Hydrodynamic diameter (based on the value average particle size as measured by DLS) for **1.Ln-AuNP Ln = a) Tb (green); b) Eu (red); c) Gd (blue)**.




Figure S9: Changes in the Eu(III) (line-like emission bands at 580, 595, 616, 650, and 700 nm) phosphorescence spectrum upon titrating **1.Eu** ($c = 1 \times 10^{-5}$ M) with **nta** (0-6 equivalents). *Inset:* Experimental binding isotherm, for the emerging emission at 615 nm (the hypersensitive $\Delta J = 2$ transition) versus equivalents of **nta**. This transition is particularly sensitive to the coordination environment of the Eu(III) centre, indicating the displacement of the metal bound water molecules and the formation of the complex with **nta**. The dramatic enhancement of red Eu(III) emission that was readily visible under a UV-lamp.




Figure S10: Changes in the Tb(III) phosphorescence spectrum upon titrating **1.Tb** ($c = 1 \times 10^{-5}$ M) with benzoic acid 0-6 equivalents. *Inset:* Experimental binding isotherm, emission intensity at 545 nm ($^5D_4 \rightarrow ^7F_5$) versus equivalents of benzoic acid.




Figure S11: The changes in the Eu(III) emission spectrum of **2.Eu** ($c = 1 \times 10^{-5}$) upon the

addition of **nta**. Inset: Experimental binding isotherm, emission intensity at 615 nm versus eqs of **nta**.




Figure S12: Evaluation of the UV-vis absorption spectrum of **1.Eu-AuNPs** ($1 \times 10^{-7} \text{M}$) in HEPES buffered solution (0.1M, ionic strength 0.1M NaCl) upon addition of **nta** 0-250 equivalents.




Figure S13: The changes in the Ln^{3+} centred emission of **1.Eu-AuNPs** ($1 \times 10^{-7} \text{M}$) in HEPES (0.1M, ionic strength 0.1M NaCl) upon the addition of **nta** 0-250 equivalents. **Inset:** The changes in the Eu^{3+} emission at 615 nm versus the number of equivalents of **nta** added.




Figure S14: Evaluation of the Eu^{3+} emission of **1.Eu-AuNPs** ($1 \times 10^{-7} \text{M}$) in HEPES buffered solution (0.1M, ionic strength 0.1M NaCl) upon addition of **tta** 0-250 equivalents. **Inset:** shows the changes in the $\text{Eu}^{3+} {}^5\text{D}_0 - {}^7\text{F}_2$ transition vs the number of equivalents added of **tta**.




Figure S15: The changes in the UV-Vis absorption spectrum of **1.Eu-AuNPs-tta** as a function of pH 2-12. **Inset:** Changes in the UV-Vis absorption band at 339 nm as a function of pH with reverse titration overlaid.





Figure S16: Evolution of the Eu^{3+} emission of **1.Eu-AuNPs-tta** with pH. **Inset:** Changes in the ${}^7\text{F}_2$ transition upon varying the pH from 2-12 (blue), reverse titration pH 12-2 (red).

a)



b)

Longitudinal relaxivity r_1 for **1.Gd** complex

Frequency	10 MHz	400 MHz	600 MHz
r_1 [$s^{-1}mM^{-1}$]	16.5	11.14	8.1

Figure S17: (a) Plot of integration versus the time delay from 1H NMR (400 MHz, D_2O) for the T_1 of **1.Gd** (2.67 mM). (b) From these measurements, the longitudinal water proton relaxivity r_1 (H_2O), which arises from **1.Gd** can be estimated by dividing the D_2O value reported in Table below by the viscosity ratio, $\eta(D_2O)/\eta(H_2O) = 1.24$. The longitudinal relaxation times of the H_2O protons in solutions of **1.Gd**, were also measured at 10 MHz and 298 K, using NMRD studies, and the corresponding relaxivities are reported in **b** and shown in the profile in **Figure S18**.




Figure S18: Longitudinal relaxivity (r_1) of the H_2O protons of **1.Gd** in H_2O at 298K (2.67 mM).




Figure S19: Plot of integration vs the delay of the values from ^1H NMR for the T_1 of **2.Gd**




Figure S20: Plot of integration versus the delay time for the T_1 of **1.Gd-AuNPs** in H_2O (2.67 mM)

Frequency MHz	10 MHz	600 MHz	400 MHz
r_1 [$\text{s}^{-1}\text{mM}^{-1}$] per Gd	16.5	8.1	11.14
r_1 [$\text{s}^{-1}\text{mM}^{-1}$] per AuNP	-	315	416.2

Figure S21: Relaxivity calculated for **1.Gd-AuNPs**




Figure S22: Longitudinal relaxivity (r_1) of the protons of **1.Gd-AuNPs** in H_2O at 25 °C, 37 °C, 49 °C.